Notable Thursday Option Activity: MDB, TECH, MHK

Bio-Techne (TECH) saw unusually high options activity with 12,118 contracts traded (≈1.2M underlying shares), equal to roughly 64% of its one‑month average daily volume (1.9M shares); the most active contract was the $65 put expiring Feb 20, 2026 with 5,001 contracts (~500,100 shares). Mohawk Industries (MHK) recorded 4,965 option contracts (≈496,500 underlying shares), about 63.8% of its one‑month ADV (778,505 shares), driven by heavy trading in the $140 call expiring Mar 20, 2026 (4,904 contracts, ~490,400 shares).

Analysis

Market structure: The concentrated flow — ~500k-share-equivalent puts in TECH and ~490k-share-equivalent calls in MHK — is large relative to each name's ADV (TECH puts ≈26% of monthly ADV, MHK calls ≈63% of ADV) and likely reflects directional bets or large institutional hedges. Immediate winners: liquidity providers, options desks (collecting elevated IV); potential losers: passive holders of TECH if downside is realized, and short-dated sellers if gamma forces squeeze. Delta/gamma hedging from dealers can amplify moves in equities over days, not fundamentals.

Risk assessment: Tail risks include an unexpected FDA/regulatory setback or revenue-guide cut for TECH and a macro/housing shock or raw-material price spike for MHK; both are low-probability but high-impact over 3–12 months. In the near-term (days–weeks) largest risk is volatility-driven — option-led flows and dealer hedges — while fundamentals play out over quarters; hidden dependency: a single block trade or structured product unwind could reverse flows abruptly.

Trade implications: For short-term tactical trades (next 5–30 days) exploit elevated IV asymmetry: prefer defined-risk option spreads rather than naked exposure. For medium-term (1–6 months) bias long MHK (housing recovery exposure) and hedged/limited-short TECH (biotech sensitivity) — size positions small (1–3% each) to limit gamma risk and use verticals to cap loss. Monitor IV percentiles, open interest shifts, and upcoming earnings/FDA/calendar events as trade triggers.

Contrarian angles: Heavy put volume in TECH may be protective hedging for larger long portfolios or a block trade, not pure bearish conviction — selling into panic could be rewarded if no fundamental catalyst appears within 30–90 days. Likewise, MHK calls could be collar/rolling activity; upside may be capped if calls are covered. Historical parallel: single-strike concentration preceded both directional moves and quick mean-reversions (see concentrated single-strike flows in 2022–23), so prefer trades that profit from realized moves, not just headline flows.

Key Decisions for Investors

• Establish a defined-risk bearish spread on TECH: buy Feb 20, 2026 $65/$50 put vertical sized to 2% portfolio notional (max loss = premium paid). Enter within 5 trading days if IV percentile for TECH puts >60; target ≥2x payoff if TECH drops ≥30% by expiry, stop-loss = 50% of premium.
• Add a tactical bullish spread on MHK: buy Mar 20, 2026 $140/$170 call vertical sized to 2% portfolio notional. Enter within 10 trading days or on a pullback of ≥5% from today’s price; set profit target 30–50% and hard stop at 12% downside in stock price or 60% premium loss.
• Implement a relative-value pair: long MHK equity (1.5% portfolio) and short TECH equity (1.5% portfolio) to express cyclical vs. defensive rotation. Rebalance monthly; unwind if macro housing starts fall >5% MoM or TECH issues an earnings/FDA shock within 30 days.